Serotonin warning for users of SSRIs

Share this article:
The FDA says development of a potentially life-threatening serotonin syndrome may occur in treatment with four selective serotonin reuptake inhibitors: Lilly's Cymbalta (duloxetine HCl) delayed release capsules, Wyeth's Effexor (venlafaxine HCL) tablets and Effexor extended release capsules, Lilly's Prozac (fluoxetine capsules and oral solution) and Lilly's Symbyax (olanzapine and fluoxetine HCL capsules).

Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.